Clinical Trial Update: Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating two Type III Group B Streptococcus polysaccharide-tetanus toxoid conjugate vaccines has completed under NIAID sponsorship.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Group Streptococcal Infection

Drugs mentioned

• GBS Type III polysaccharide-tetanus toxoid conjugate vaccine (Formulation 1)
• GBS Type III polysaccharide-tetanus toxoid conjugate vaccine (Formulation 2)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Bacterial Infections, Group B Streptococcus | Phase 1 | Status: COMPLETED